Cancer vaccine - MolMed/San Raffaele Scientific Institute

Drug Profile

Cancer vaccine - MolMed/San Raffaele Scientific Institute

Alternative Names: M3TK

Latest Information Update: 17 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MolMed
  • Developer MolMed; Scientific Institute San Raffaele
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 17 Sep 2015 No recent reports of development identified - Phase-I/II for Malignant melanoma in Italy (IV)
  • 29 Jun 2009 Phase-I/II development is ongoing in Italy
  • 30 Nov 2007 This vaccine is available for licensing in all territories except Asia (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top